Impact of Diabetes on Long-Term Outcome After Primary Angioplasty
暂无分享,去创建一个
G. Stone | H. Suryapranata | Bas L van der Hoeven | M. Schalij | V. Pasceri | G. De Luca | C. Spaulding | L. Thuesen | H. Kelbæk | C. Kaiser | E. Di Lorenzo | R. Violini | T. Chechi | G. Spaziani | C. Musto | M. Dirksen | L. S. Díaz de la Llera | M. A. Vink | Bas L. van der Hoeven
[1] H. Suryapranata,et al. A meta-analytic overview of thrombectomy during primary angioplasty. , 2013, International journal of cardiology.
[2] G. Stone,et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. , 2012, Archives of internal medicine.
[3] E. D. Lorenzo,et al. Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors and BMS or DES , 2010, Journal of Thrombosis and Thrombolysis.
[4] D. Dudek,et al. Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry. , 2010, Atherosclerosis.
[5] D. Dudek,et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. , 2009, Atherosclerosis.
[6] G. De Luca,et al. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials , 2009, European heart journal.
[7] G. De Luca,et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. , 2009, American heart journal.
[8] G. De Luca,et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty , 2009, Thrombosis and Haemostasis.
[9] G. De Luca,et al. Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. , 2009, The American journal of emergency medicine.
[10] G. De Luca,et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. , 2009, JACC. Cardiovascular interventions.
[11] G. Biondi-Zoccai,et al. Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. , 2008, Annals of emergency medicine.
[12] G. Stone,et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. , 2008, International journal of cardiology.
[13] R. Kornowski,et al. Impaired fasting glucose and outcomes of ST-elevation acute coronary syndrome treated with primary percutaneous intervention among patients without previously known diabetes mellitus. , 2008, American heart journal.
[14] R. Gibbons,et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). , 2007, The American journal of cardiology.
[15] M. Ishihara,et al. Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. , 2007, The American journal of cardiology.
[16] Johan Lindbäck,et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.
[17] E. Bramucci,et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.
[18] Harlan M. Krumholz,et al. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2006, Circulation.
[19] J. Ottervanger,et al. Impact of routine stenting on clinical outcome in diabetic patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. , 2006, Diabetes care.
[20] J. Ottervanger,et al. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. , 2005, The American journal of cardiology.
[21] I. Iakovou,et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.
[22] J. Ottervanger,et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients , 2005, Heart.
[23] G. Parodi,et al. Abciximab-Supported Infarct Artery Stent Implantation for Acute Myocardial Infarction and Long-Term Survival: A Prospective, Multicenter, Randomized Trial Comparing Infarct Artery Stenting Plus Abciximab With Stenting Alone , 2004, Circulation.
[24] G. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[25] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[26] D. Antoniucci,et al. Angiographic findings, time course of regional and global left ventricular function, and clinical outcome in diabetic patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty. , 2003, The American journal of cardiology.
[27] J. J. Griffin,et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.
[28] K. Nishioka,et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. , 2001, Journal of the American College of Cardiology.
[29] J. Cornel,et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. , 2001, International journal of cardiology.
[30] A. M. Lefer,et al. Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. , 2001, American journal of physiology. Endocrinology and metabolism.
[31] G. Paolisso,et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. , 2000, Circulation.
[32] H. Gerstein,et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview , 2000, The Lancet.
[33] S. Kaul,et al. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. , 2000, Journal of the American College of Cardiology.
[34] M. Hadamitzky,et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.
[35] A. Nitenberg,et al. Impairment of Coronary Vascular Reserve and ACh-Induced Coronary Vasodilation in Diabetic Patients With Angiographically Normal Coronary Arteries and Normal Left Ventricular Systolic Function , 1993, Diabetes.
[36] J. Moses,et al. Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery , 2004 .
[37] T. Sakuma,et al. Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: the role of microthromboemboli. , 2003, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.